[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334844-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334844-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","identification-of-barriers-to-implementation-of-precision-oncology-in-patients-with-rare-cancers","Identification of barriers to implementation of precision oncology in patients with rare cancers","","Established treatment options for rare cancers are constrained by a small patient population, limiting how fully comprehensive genomic profiling (CGP) can enable precision oncology. This retrospective study enrolled patients who received CGP testing between September 2019 and June 2021. Molecular results guided the use of molecularly targeted drugs or immune checkpoint inhibitors, with univariate and multivariate analyses linking patient factors to targeted-drug proportions. Among 333 rare-cancer patients, most showed actionable changes, yet limited drug options with clinical evidence formed a key barrier, supporting evidence-level A–D testing.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/identification-of-barriers-to-implementation-of-precision-oncology-in-patients-with-rare-cancers/334844/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/identification-of-barriers-to-implementation-of-precision-oncology-in-patients-with-rare-cancers/334844.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address regarding rare cancers and precision oncology?","Question",{"text":63,"@type":64},"Treatment options for rare cancers are limited due to few patients, which can prevent comprehensive genomic profiling from being fully leveraged for precision oncology.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was CGP testing used in the study, and what were patients treated with?",{"text":68,"@type":64},"Patients underwent CGP testing, and based on results they received molecularly targeted drugs or immune checkpoint inhibitors.",{"name":70,"@type":61,"acceptedAnswer":71},"What main barrier to implementing precision oncology was identified for rare cancers?",{"text":72,"@type":64},"The limited number of molecularly targeted drugs with clinical evidence was identified as a potential barrier to CGP testing utility in rare cancers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334844,1790535930,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Received: 18 December 2023  \nRevised: 9 March 2024  \nAccepted: 19 March 2024  \nDOI: 10. 1111/cas.16165  \nOR I G I NAL ART I C L E  \nIdentification of barriers to implementation of precision oncology in patients with rare cancers  \nShigemasa Takamizawa1  | Takafumi Koyama1  | Kuniko Sunami2  |  \nKazuki Sudo1,3  | Makoto Hirata4 | Takashi Kubo5 | Kayoko Tao6 | Hourin Cho4  | Yoshitaka Narita7 | Ken Kato8,9  | Naoya Yamazaki10  | Yuichiro Ohe11  |  \nTakuji Okusaka12 | Yoshiyuki Matsui13 | Chitose Ogawa6 | Kan Yonemori1,3  | Noboru Yamamoto1   \n1Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan 2Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo, Japan 3 Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan 4Department of Genetic Medicine and Services, National Cancer Center Hospital, Tokyo, Japan  \n5Division of Translational Genomics, National Cancer Center-Exploratory Oncology Research and Clinical Trial Center, Tokyo, Japan 6Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan  \n7Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan 8 Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan 9Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan 10 Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan  \n11Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan  \n12Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan 13 Department of Urology, National Cancer Center Hospital, Tokyo, Japan  \nCorrespondence  \nTakafumi Koyama, Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo 104-0045, Japan.  \nEmail: [takoyama@ncc.go.jp](takoyama@ncc.go.jp)  \nAbstract  \nEstablished treatment options for rare cancers are limited by the small number of patients. The current comprehensive genomic profiling (CGP) testing might not fully exploit opportunities for precision oncology in patients with rare cancers. Therefore, we aimed to explore the factors associated with CGP testing utility in rare cancersand identify barriers to implementing precision oncology. Patients who underwent CGP testing at our institution between September 2019 and June 2021 were enrolled in this retrospective study. Based on their results, the patients received molecularly targeted drugs or immune checkpoint inhibitors. Univariate and multivariate analyses evaluated the association between patient characteristics and the proportion of patients receiving molecularly targeted drugs. Overall, 790 patients underwent CGP testing. Among them, 333 patients with rare cancers were identified, of whom 278  \nAbbreviations: CGP, comprehensive genomic profiling; MSI, microsatellite instability; NCCH, National Cancer Center Hospital; NGS, next-generation sequencing; OS, overall survival; PARP, poly (ADP-ribose) polymerase; PFS, progression-free survival; PR, partial response; TMB, tumor mutation burden.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2024 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.  \n(83 . 5%) had actionable genomic alterations, 127 (38 . 1%) had druggable genomic alterations, and 25 (7. 5%) received genomically matched therapy. The proportion of patients receiving molecularly targeted drugs was significantly higher among those with treatment options with evidence levels A–D (8 .7%) than those without treatment options with evidence levels A–D (2 .9%) . A potential barrier to CGP testing utility in rare cancers ","cbCaikFaHoz4okJB","https://ap.wps.com/l/cbCaikFaHoz4okJB","pdf",1141173,13,"English","# Abstract\n## Key methods and study design\n## Main findings on rare-cancer patients\n## Identified barriers and proposed approach\n# Introduction\n## Precision oncology and CGP testing\n## Clinical utility variability across settings\n## Challenges and rationale for rare cancers","[{\"question\":\"What problem does the study address regarding rare cancers and precision oncology?\",\"answer\":\"Treatment options for rare cancers are limited due to few patients, which can prevent comprehensive genomic profiling from being fully leveraged for precision oncology.\"},{\"question\":\"How was CGP testing used in the study, and what were patients treated with?\",\"answer\":\"Patients underwent CGP testing, and based on results they received molecularly targeted drugs or immune checkpoint inhibitors.\"},{\"question\":\"What main barrier to implementing precision oncology was identified for rare cancers?\",\"answer\":\"The limited number of molecularly targeted drugs with clinical evidence was identified as a potential barrier to CGP testing utility in rare cancers.\"}]","Identification of barriers to implementation of precision oncology in patients with rare cancers | PDF",1790008530,33]